– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, cardiovascular disease, and Neuroscience, each representing a blockbuster opportunity –

– Announces TRITON Phase 3 program for next-generation TTR silencer nucresiran in ATTR-CM and hATTR-PN, targeting durable franchise leadership –

– Provides details about Phase 3 cardiovascular outcomes trial for zilebesiran, poised to transform the treatment of hypertension in patients with high CV risk –

– Highlights new clinical programs, including for Huntington’s disease, bleeding disorders, and type 2 diabetes –

– Shares platform advances, including potential best-in-class delivery solutions for adipose, muscle, heart, and kidney, and for crossing the . . .